Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PDC*lung01, PDC*lung01
Pharma Mar S.A.
Non-small-cell lung cancer
1 trial -
AN OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE SAFETY AND EFFICACY IN PARTICIPANTS TREATED WITH CRN04894
Pharma Mar S.A.
CONGENITAL ADRENAL HYPERPLASIA
1 trial -
AP02 High, AP02 Low, AP02 Placebo
Pharma Mar S.A.
Idiopathic Pulmonary Fibrosis (IPF)
1 trial -
AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki
Pharma Mar S.A.
Rheumatoid Arthritis
1 trial -
AP31969, AP31969, The placebo tablets contain the same excipient as in the active IMP, but without AP31969. All tablet strengths containing AP31969 as well as placebo tablets are visually identical., AP31969, AP31969
Pharma Mar S.A.
Atrial fibrillation
1 trial -
AP707, Placebo
Pharma Mar S.A.
Borderline personality disorder
1 trial -
ART0380, ART0380, GEMCITABINE , ART0380, IRINOTECAN , ART0380
Pharma Mar S.A.
Advanced or Metastatic Solid Tumours
1 trial -
ASPAVELI 1 080 mg solution for infusion
Pharma Mar S.A.
complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)
1 trial -
ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion
Pharma Mar S.A.
Paroxysmal Nocturnal Hemoglobinuria
1 trial -
Actrapid 100 international units/ml solution for injection in vial, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, SODIUM CHLORIDE, Natriumklorid Fresenius Kabi 9 mg/ml, spädningsvätska för parenteral användning, Albumin Baxalta 200 g/l infusionsvätska, lösning, Glucos Fresenius Kabi 200 mg/ml infusionsvätska, lösning, A24110He
Pharma Mar S.A.
Moderate to severe hypertriglyceridemia
1 trial -
An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies
Pharma Mar S.A.
Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy
1 trial -
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes
Pharma Mar S.A.
transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic syndromes
1 trial -
Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet
Pharma Mar S.A.
Polymyalgia rheumatica
1 trial -
Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet
Pharma Mar S.A.
Idiopathic membranous nephropathy and severe proteinuria
1 trial -
Atropine Sulfate 0.025% Eye Drops, solution in single-dose container, Atropine Sulfate 0.005% Eye Drops, solution in single-dose container, Placebo Atropine Sulfate Eye Drops, solution in single-dose container, Atropine Sulfate 0.01% Eye Drops, solution in single-dose container, Atropine Sulfate 0.05% Eye Drops, solution in single-dose container
Pharma Mar S.A.
Myopia progression in children
1 trial -
BCX17725
Pharma Mar S.A.
Netherton Syndrome
1 trial -
BNT116, LIBTAYO 350 mg concentrate for solution for infusion.
Pharma Mar S.A.
Advanced Non-Small Cell Lung Cancer
1 trial -
BRONCHO-VAXOM Children Capsules placebo, BRONCHO-VAXOM, 3,5mg, kapsułki
Pharma Mar S.A.
Recurrent wheezing
1 trial -
BW-20805 Injection
Pharma Mar S.A.
Hereditary Angioedema
1 trial -
Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1
Pharma Mar S.A.
Alzheimer’s Disease
1 trial -
Bexmarilimab
Pharma Mar S.A.
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
1 trial -
CARBOPLATIN , PACLITAXEL , NP137, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Pharma Mar S.A.
Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.
1 trial -
CND261
Pharma Mar S.A.
Active, treatment refractory, ANCA-IgG-positive associated vasculitis
1 trial -
CRD-4730, CRD-4730 matching placebo
Pharma Mar S.A.
Catecholaminergic Polymorphic Ventricular Tachycardia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources